| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56b29cff990807d0701e74876774dffc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-186
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-00 |
| filingDate |
2017-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c413207b499353083a1948da50c5efe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83e66dc1db2cb3ddd8ad0b77b1be63e3 |
| publicationDate |
2020-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2725153-C1 |
| titleOfInvention |
Pharmaceutical composition containing mineralocorticoid receptor antagonist, and application thereof |
| abstract |
FIELD: medicine; pharmaceuticals. n SUBSTANCE: group of inventions relates to the pharmaceutical industry, in particular to a pharmaceutical composition for treating chronic kidney disease in a human, comprising a compound I and one or more pharmaceutically acceptable carriers, wherein composition is an oral dosage form containing 0.1 to 1.0 mg of compound I for single use. Also disclosed are a method of treating and/or preventing chronic kidney disease by administering the above composition to a human patient in need thereof and using the composition for preparing a medicament for treating and/or preventing chronic kidney disease. n EFFECT: group of inventions provides establishing a specific range of doses for the safe and effective treatment of chronic renal disease with no side effects of hyperkalemia. n 23 cl, 2 dwg, 11 tbl, 9 ex |
| priorityDate |
2016-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |